bioAffinity Technologies, Inc. (BIAFW)

What does bioAffinity do?

bioAffinity Technologies is a biotechnology company founded in 2014 and based in San Antonio, Texas. The company develops and commercializes CyPath Lung, a non-invasive diagnostic test that detects lung cancer in its early stages by analyzing a patient’s sputum — the mucus and phlegm a person coughs up. Using flow cytometry technology, the test identifies cellular characteristics and abnormalities that signal the presence of lung cancer or pre-cancerous change. The company completed its initial public offering in September 2022, listing on the Nasdaq Capital Market under the ticker BIAF, with warrants trading as BIAFW. The business sits at the intersection of oncology and diagnostic technology — two areas attracting intense investment and clinical focus because early detection of cancer dramatically improves survival rates and treatment outcomes.

Why early lung cancer detection matters

Lung cancer is the leading cause of cancer death in both men and women globally. When caught early, particularly at stage 1A, five-year survival rates exceed eighty percent; at late stages, they fall below ten percent. The challenge is that most lung cancers cause no symptoms until they are advanced. Screening is therefore the opportunity: getting at-risk individuals — primarily smokers and former smokers — tested regularly to catch tumors when they are still small and manageable. Current screening relies on low-dose CT imaging, which is expensive, exposes patients to radiation, has a high false-positive rate that leads to unnecessary follow-up biopsies, and misses some early cancers. There is substantial demand for a simple, inexpensive, non-invasive test that can accurately identify early cancer before a CT scan even becomes necessary.

CyPath Lung addresses that gap. A patient provides a sputum sample (they cough into a cup), the sample is processed using flow cytometry to examine cell populations and identify cancer-associated changes, and results come back within days. The test requires no radiation, is non-invasive, and can be administered in a doctor’s office. Clinical validation data released by bioAffinity has shown the test achieves approximately ninety-two percent sensitivity, eighty-seven percent specificity, and eighty-eight percent accuracy for detecting lung cancer in nodules smaller than twenty millimeters — exactly the size range where early intervention is most effective.

The competitive moat: technology and validation

bioAffinity’s central advantage is having developed and clinically validated a diagnostic that works and that competitors have not yet replicated. Flow cytometry for cancer detection is not new — it is a standard laboratory technique — but the specific application to sputum for lung cancer, the algorithms that interpret cell populations, and the clinical data proving diagnostic accuracy are proprietary to bioAffinity. The company has patents covering the test and its methodology, which provides legal protection against direct copying.

The second moat is clinical validation. Developing a diagnostic is one thing; proving to doctors, hospitals, and insurers that it works is another. bioAffinity has published clinical trial data and case studies demonstrating CyPath Lung’s sensitivity and specificity. That validation is a material asset. Competitors entering the market would need to generate equivalent or better clinical data, which requires time, money, and often collaboration with academic medical centres and patient registries. The longer bioAffinity operates and accumulates real-world use data, the more evidence it can publish, and the more entrenched the test becomes in clinical practice.

The third element is regulatory clearance. CyPath Lung operates under FDA clearance via the 510(k) pathway, meaning the FDA has determined it is substantially equivalent to existing predicates and safe and effective. That clearance removes a major barrier to adoption. A competitor would need to obtain its own regulatory clearance before selling, a process that takes time and carries technical and regulatory risk.

The moat is real but has an expiration date. Once a diagnostic test is well-established and the science is published, other companies will develop similar tests. The barrier is not insurmountable — the core technology is flow cytometry, which is widely available — but first-mover advantage and an installed base of clinicians familiar with CyPath Lung matter. For bioAffinity to maintain competitive position, it must keep innovating: expanding to detect other cancers, improving sensitivity and specificity, building a large volume of case data that educates the market, and staying ahead of rivals on pricing and distribution.

How the business makes money and the distribution challenge

bioAffinity generates revenue by selling the test to patients. The test is ordered by pulmonologists, primary-care physicians, or occupational-medicine doctors. The patient or their insurer pays for the test, which is then performed by a diagnostic laboratory (typically operated by bioAffinity or a partner). Revenue per test varies based on insurance coverage and the setting but is generally in the several-hundred-dollar range — a price point that is well below a CT scan but higher than a simple blood test.

The company’s growth depends on test volume, which depends on adoption among physicians and reimbursement coverage by insurance companies. Building that adoption requires education, marketing to doctors, and the gradual accumulation of case studies and clinical evidence showing the test prevents unnecessary downstream procedures or catches cancers others miss. Reimbursement is the other critical gate: if insurers deny coverage or set reimbursement rates too low, adoption will be slow. In the early stages, bioAffinity is working to secure coverage codes from Medicare and commercial insurers, which takes regulatory and commercial negotiation.

The competitive risk is that larger diagnostics companies — like Quest Diagnostics or LabCorp — or well-funded biotech rivals might develop competing sputum-based or blood-based early cancer detection tests. Roche, for instance, has invested heavily in liquid biopsy technology. If a well-capitalized competitor enters and matches bioAffinity’s sensitivity and specificity while leveraging existing distribution infrastructure, bioAffinity’s growth could be constrained.

The financial picture and the path to profitability

bioAffinity is a typical early-stage diagnostics company: pre-revenue or early-revenue, with cumulative losses and cash burn. The company raised roughly seven point eight million dollars gross in its September 2022 IPO, and is burning cash to fund R&D, regulatory efforts, and commercialization. The path to profitability requires scaling test volume to a point where fixed costs are absorbed by revenue. For a diagnostic test company, that inflection point often comes at test volumes in the hundreds of thousands per year, at which point unit economics improve substantially.

Recent reports indicate that bioAffinity achieved record revenue in 2025 with test units performed more than doubling year-over-year, suggesting the adoption curve is accelerating. That is a positive sign, but the company remains loss-making and dependent on available cash and investor confidence to reach profitability.

How to research bioAffinity

Start with the company’s SEC filings, including the 10-K (SEC CIK 0001712762) and quarterly 10-Qs, which break down revenue by source, detail cash burn, describe competitive landscape, and explain clinical and regulatory status. Review the clinical trial data and case studies bioAffinity has published; these are available on the company’s website and in peer-reviewed journals. Check the status of insurance reimbursement coverage — whether Medicare or major commercial plans have approved CyPath Lung and at what payment rate — because reimbursement is a key inflection point for adoption. Monitor physician adoption through statements in earnings calls and marketing announcements; rapid increases in test volume are a positive sign. Watch for competitive announcements from larger diagnostics companies; if rivals announce competing tests, evaluate their clinical claims and timeline to market. Assess cash runway: how long will the company’s available cash sustain operations before it needs another fundraise? Equity dilution from future financing rounds could be significant if bioAffinity is not yet on a path to profitability. Any changes to FDA policy around diagnostic tests, or new insurance reimbursement codes related to lung cancer screening, could materially affect the market opportunity. As with any public security, bioAffinity’s shares trade at market prices; nothing here is investment advice.